As reported by in the Montrose Review, a £1.46m R&D grant will not only help secure GlaxoSmithKline’s future at the Montrose site, but will create 25 jobs and safeguard 280.
The research and development grant has been made by the Scottish Enterprise and was announced by Scottish finance secretary John Swinney on Monday. It is hoped that the grant will support GSK’s innovation and help maintain Scotland’s position in the pharmaceutical’s industry. Speaking of the news, Swinney stated,
“The Scottish Government and our enterprise agencies are doing all we can to build sustainable economic growth for Scotland.
“This investment by GlaxoSmithKline in Montrose is looking towards the future and I’m encouraged that a world leading company is showing this commitment to the area.
“Scotland is globally renowned for innovation, enterprise and technology. The quality and skills of our workforce in life sciences have played an important part in the company’s decision, as has the research excellence of our institutions and the competitiveness of our business environment.
“The hard work by our partners at Scottish Enterprise and Scottish Development International also deserves praise. They have built-up an excellent understanding of this company and provided the most relevant support when required.”
Andy Ross, GlaxoSmithKline Montrose site director said: “We are very grateful to Scottish Enterprise for all their efforts in relation to the research and development grant.
“Their financial support will allow us to provide the right people, plant and expertise at a critical time for the GSK Montrose site as we look to introduce innovative new processes so as to maintain our global cost effectiveness.”
BioCity Nottingham news
